Cullinan Therapeutics (CGEM) Net Income: 2021-2023
Historic Net Income for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Net Income rose 5.56% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 241.97%. This contributed to the annual value of -$167.6 million for FY2024, which is 8.04% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Net Income of -$25.6 million as of Q4 2023, which was up 34.76% from -$39.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Net Income registered a high of $174.1 million during Q2 2022, and its lowest value of -$58.1 million during Q1 2023.
- Moreover, its 3-year median value for Net Income was -$25.2 million (2022), whereas its average is -$9.4 million.
- Data for Cullinan Therapeutics' Net Income shows a peak YoY increase of 1,158.85% (in 2022) and a maximum YoY decrease of 1,006.27% (in 2022) over the last 5 years.
- Cullinan Therapeutics' Net Income (Quarterly) stood at -$34.2 million in 2021, then grew by 20.87% to -$27.1 million in 2022, then climbed by 5.56% to -$25.6 million in 2023.
- Its Net Income was -$25.6 million in Q4 2023, compared to -$39.2 million in Q3 2023 and -$32.2 million in Q2 2023.